Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC

/PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China,...

Related Keywords

China ,Taiwan ,Shanghai ,Hong Kong ,Howe Li ,Nicholas Desjardins ,Brian Zhang ,China National Medical Products Association ,Himalaya Therapeutics ,Greater China ,Conditionally Active Biologics ,Drug Evaluation ,Mainland China ,Himalaya Therapeutics Sezc ,